PT - JOURNAL ARTICLE AU - Lee, Ann Joo AU - Kraemer, Dale F. AU - Kanar, Ozdemir AU - Berry, Andrew C. AU - Smotherman, Carmen AU - Eid, Emely TI - Immunomodulator and Biologic Agent Effects on Sleep Quality in Patients With Inflammatory Bowel Disease DP - 2018 Mar 20 TA - Ochsner Journal PG - 76--80 VI - 18 IP - 1 4099 - http://www.ochsnerjournal.org/content/18/1/76.short 4100 - http://www.ochsnerjournal.org/content/18/1/76.full SO - Ochsner J2018 Mar 20; 18 AB - Background: Inflammatory bowel disease (IBD) can disrupt normal sleep physiology and amplify a negative perception about quality of life. Evidence suggests increased circulation of inflammatory cytokines, such as tumor necrosis factor–alpha and interleukin-1, may play a role.Methods: A total of 56 patients completed the Pittsburgh Sleep Quality Index (PSQI) to measure 7 sleep domains: sleep quality, sleep latency, sleep duration, sleep efficacy, sleep disturbance, sleep medications, and daytime dysfunction. Domain scores were summed to determine the presence or absence of sleep impairment. We compared patients taking immunomodulators or biologic agents to patients not on immunomodulator or biologic agent therapy. Demographics and IBD-related clinical information were collected to adjust for potential confounders that may secondarily affect sleep, such as body mass index, depression/anxiety, and sleep-affecting medications.Results: The majority of patients with IBD (46 [82%]) reported poor sleep quality; 22 (79%) of the patients taking immunomodulators or biologic agents and 24 (86%) of the patients not on these therapies had a global PSQI score ≥5, suggestive of poor sleep quality. However, we found no significant difference between the 2 groups. When we analyzed the 7 PSQI sleep domains individually, we found improved sleep duration in the group taking immunomodulators or biologic agents compared to the group not on therapy, although the difference was not statistically significant.Conclusion: The majority of patients with IBD experience some degree of sleep impairment, and treatment with immunomodulators and biologic agents does not appear to improve sleep quality. A multicenter study with a larger sample size is warranted to better assess the diverse population of patients with IBD and the factors that impact their sleep. Routine assessment of sleep quality during IBD clinical encounters is recommended.